ArticleJournal of paediatrics and child health2025
An Australian Paediatric Retrieval Service Riding the Wave of Invasive Group A Streptococcal Disease From 2022 to 2024.
Article in Journal of paediatrics and child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased burden of invasive group A streptococcal disease among Australian children, 2023-2024: a prospective cohort study.The Lancet regional health. Western Pacific · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrom late 2022, there was an increase in cases of invasive group A streptococcus (iGAS) reported in the Northern Hemisphere and there was a similar increase noted in the referrals to the Newborn and Paediatric Emergency Transport service (NETS NSW), in the state of New South Wales (NSW), Australia. This study describes the clinical characteristics and outcomes of children referred to NETS NSW with iGAS disease.
methodsA retrospective cohort of children referred to NETS NSW for management of iGAS disease between 1st November 2022 to 29th February 2024. Patients included had a confirmed diagnosis of iGAS disease (i.e., on detection of S. pyogenes from a sterile site). Clinical characteristics and outcome data were collected from the medical record.
resultsSeventy-seven cases were referred to NETS NSW of children with confirmed iGAS disease and seventy were retrieved by NETS NSW. Three patients died in the referring hospital; one was retrieved by an interstate service and three improved and stayed locally. A male predominance of 44/77 (57%) was noted, most were children of preschool age (median 4.2 years QR 1.95-8.05), presenting with pneumonia (52/77, 67.5%), septic arthritis (12/77, 16%), or rash 37/68 (54%). There were high rates of bacteraemia (38/77, 49%) and increased mean serum lactate (4.8 mmol/L ± 3.3). High clinical acuity was seen, with most cases retrieved to paediatric intensive care unit (52/77, 68%), often managed with mechanical ventilation (36/77, 47%), effusion drainage (50/77, 65%) and 24/77 (27%) referred via NETS NSW for the Kids ECMO Referral Service (KERS). IVIg was added for 31/64 cases (48%) as supportive care, along with antibiotic therapy. Four children did not survive.
conclusionThe prevalence of iGAS disease referrals to NETS NSW significantly increased from late 2022 to early 2024. There was a high service demand for NETS NSW to retrieve critically unwell preschool-aged children requiring critical stabilisation and transfer to a paediatric intensive care unit (PICU).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.